oral semaglutide phase 3 Efficacy and safety of by subgroups of patient characteristics in the PIONEER programme Oral semaglutide drops - No

The NIHR Be Part of Research platform (bepartofresearch.nihr.ac.uk) and the ClinicalTrials.gov database list ongoing studies, and some UK sites may be participating in the TRIUMPH programme

Immunomodulatory NPs are particularly relevant given the rising prevalence and chronic burden of diseases such as RA, which is associated with persistent inflammation and pain in small joints

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes mellitus and, more recently, obesity

Behrens M et al

Always remember to follow the instructions that come with the package, step by step, to make sure you're using it correctly